Increasing malaria diagnosis in the private sector in Tanzania

Completed

Conditions: Malaria
Infections and Infestations

Registration Number: ISRCTN14115509

Lead Sponsor: Clinton Health Access Initiative

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: All

Target Recruitment: 1500

Inclusion Criteria

ADDO dispenser inclusion criteria:
1. A certified ADDO dispenser in Kilosa or Kilombero District
2. Attended and passed the two-day RDT training

Survey participants (exit interview):
1. 18 years or older unless accompanied by a parent, guardian, or family member 18 years or older
2. A patient presenting at the ADDO with fever, suspected malaria, or wishing to purchase an RDT or antimalarial
OR
3. A customer at an ADDO wishing to purchase an antimalarial for someone else

Exclusion Criteria

ADDO dispenser exclusion criteria
1. An ADDO employee who is not a certified ADDO dispenser in Kilosa or Kilombero District
2. Any ADDO employee in Mvomero District

Survey participants (exit interview):
1. A patient presenting at the ADDO with symptoms of severe illness or reasons other than fever, suspected malaria, or wishing to purchase an RDT or antimalarial
2. A customer at an ADDO wishing to purchase something other than for fever or suspected malaria
3. Children under 18 years old and unaccompanied by a parent, guardian, or family member 18 years or older

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Blood-based diagnosis of malaria rate is measured by the percentage of suspected malaria customers that received an RDT in an ADDO at baseline and 13 months.

Secondary Outcome Measures

Name	Time	Method
1. Availability of blood-based diagnostic tests is measured by the percentage of ADDOs with a trained dispenser and RDTs in stock at baseline and 13 months<br>2. Positive adherence is measured by the percentage of customers who tested positive with an RDT and also purchased an artemisinin-combination therapy (ACT) at baseline and 13 months<br>3. Negative adherence is measured by the percentage of customers who tested negative with an RDT and also purchased an artemisinin-combination therapy (ACT) at baseline and 13 months<br>4. Affordability is measured by reported price paid for an RDT at baseline and 13 months<br>5. RDT performance safety is measured using a 17-point checklist at 1, 4, 8, and 13 months<br>6. RDT disposal safety is measured by the percentage of shops disposing of waste at a public health facility at 1, 4, 8, and 13 months